Pipetting Made Easy - Part 3: Pipette Selection

Sample preparation is one of the most important stages of the analytical process in an LC-MS/MS laboratory. The quality of this step has a significant impact on result reproducibility, laboratory throughput, and the overall efficiency of the analytical method. In our laboratory, we therefore use the <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1914">Organomation 80 Position MULTIVAP® nitrogen evaporator</a> for sample preparation in the determination of steroid hormones and in our newly developed method for the determination of vitamins B3 (nicotinamide), B5 (pantothenic acid), and B7 (biotin). The system has proven to be a reliable solution for the rapid and reproducible evaporation of organic solvents.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/SPADIA_LAB_Organomation_80_Position_MULTIVAP_2975e64fc4.jpg" alt="SPADIA LAB: Organomation 80 Position MULTIVAP® nitrogen evaporator" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_SPADIA_LAB_Organomation_80_Position_MULTIVAP_2975e64fc4.jpg 117w," sizes="100vw" width="1600" height="2133">In our workflow, the instrument is primarily used to evaporate methanol and methyl tert-butyl ether (MTBE) following sample extraction. Rapid removal of these solvents is an important step before subsequent sample reconstitution and LC-MS/MS analysis. Uniform nitrogen flow combined with controlled heating enables efficient solvent evaporation while maintaining high reproducibility throughout sample preparation.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/SPADIA_LAB_Stanoveni_volnych_plazmatickych_metanefrinu_pomoci_kapalinove_chromatografie_s_tandemovou_hmotnostni_detekci_4adb0c95ca.jpg" alt="SPADIA LAB: Laboratory of Clinical Biochemistry Ostrava, Department of Chromatography and Spectrometry" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_SPADIA_LAB_Stanoveni_volnych_plazmatickych_metanefrinu_pomoci_kapalinove_chromatografie_s_tandemovou_hmotnostni_detekci_4adb0c95ca.jpg 235w," sizes="100vw" width="800" height="533">The instrument combines nitrogen blow-down evaporation with controlled heating using an aluminum dry block. This combination enables gentle analyte concentration while reducing evaporation time. A major advantage is the ability to process up to 80 samples simultaneously, significantly increasing laboratory capacity when analyzing larger sample batches.The MULTIVAP is equipped with digital temperature control over a range of 30–120 °C, maintaining the set temperature with an accuracy of approximately ±2 °C. Uniform nitrogen distribution through stainless-steel needles provides consistent evaporation conditions across all positions. Another practical feature is the ability to independently shut off the nitrogen supply to individual rows of ten samples, enabling more efficient gas consumption when working with smaller batches. The instrument also provides nitrogen flow control from 0–25 L/min and features a precision-machined aluminum block optimized for a specific tube diameter, ensuring efficient heat transfer and high process reproducibility.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/SPADIA_LAB_Organomation_80_Position_MULTIVAP_2_468fbd4d0d.jpg" alt="SPADIA LAB: Organomation 80 Position MULTIVAP® nitrogen evaporator" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_SPADIA_LAB_Organomation_80_Position_MULTIVAP_2_468fbd4d0d.jpg 117w," sizes="100vw" width="1600" height="2133">In everyday operation, we particularly appreciate the stable performance, straightforward operation, and ability to process a large number of samples in parallel without compromising sample preparation quality. The instrument has proven effective both for routine steroid hormone analyses and during the development of new LC-MS/MS methods for the determination of B vitamins. Its major benefits include not only shorter sample preparation times but also highly reproducible evaporation across the entire sample batch.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/SPADIA_Laborator_chromatografie_a_spektometire_Ostrava_2_fdaa4ab8e5/SPADIA-Laborator-chromatografie-a-spektometire-Ostrava-2.jpg" alt="SPADIA LAB: Laboratory of Clinical Biochemistry Ostrava, Department of Chromatography and Spectrometry" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_SPADIA_Laborator_chromatografie_a_spektometire_Ostrava_2_fdaa4ab8e5/thumbnail_SPADIA-Laborator-chromatografie-a-spektometire-Ostrava-2.jpg 234w," sizes="100vw" width="800" height="533">Based on our experience, we consider the Organomation MULTIVAP a robust and reliable laboratory instrument that has become an integral part of our analytical workflow. Its combination of high sample capacity, efficient nitrogen utilization, and precise temperature control makes it a suitable solution for laboratories using modern LC-MS/MS methods.<h3>What Other Tests Are Performed by the Laboratory of Clinical Biochemistry Ostrava, Department of Chromatography and Spectrometry?</h3><ul><li>Vitamins: B1, B2, B6, A, C, D2 (25-OH), D3 (25-OH), E, coenzyme Q10</li><li>Ions, trace elements, and toxic elements: magnesium in erythrocytes, zinc, copper, selenium, manganese, chromium, cobalt, molybdenum, titanium, aluminum, nickel, cadmium, lead, mercury</li><li>Fatty acid profile analysis: including determination of the Omega-6/Omega-3 ratio and three additional nutritional indicators</li></ul><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/SPADIA_LAB_LC_MS_MS_system_pro_mereni_mastnych_kyselin_na_oddeleni_chromatografie_a_spektrometrie_SPADIA_LAB_8227b1ac3f.jpg" alt="SPADIA LAB: LC-MS-MS system for measuring fatty acids in the Chromatography and Spectrometry Department" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_SPADIA_LAB_LC_MS_MS_system_pro_mereni_mastnych_kyselin_na_oddeleni_chromatografie_a_spektrometrie_SPADIA_LAB_8227b1ac3f.jpg 208w," sizes="100vw" width="2284" height="1713"><ul><li>Therapeutic drug monitoring (TDM): digoxin, theophylline, amiodarone, antibiotics, antiepileptics, benzodiazepines, antipsychotics, antidepressants</li><li>Toxicology: toxicological screening (amphetamines, benzodiazepines, cannabinoids, cocaine, tricyclic antidepressants, opiates, methadone, kratom), toxicological confirmation (LC-MS/MS, GC/MS)</li><li>Biogenic amines and their metabolites: catecholamines, metanephrines, serotonin, vanillylmandelic acid, homovanillic acid, 5-hydroxyindoleacetic acid</li><li>Steroid hormones: dihydrotestosterone, androstenedione, 17-OH-progesterone</li><li>Porphyria diagnostics: 5-aminolevulinic acid, porphobilinogen</li><li>Other specialized tests: fecal hemoglobin (FOB), serum amyloid A, complement activity (CH50), angiotensin-converting enzyme, bile acids, beta-hydroxybutyrate, urinary oxalates</li><li>Veterinary testing: CRP, SAA (serum amyloid A), SDMA (symmetric dimethylarginine)</li></ul>

Efficient Sample Evaporation Using the Organomation MULTIVAP® Nitrogen Evaporator

Our Library never stops expanding. What are the most recent contributions to LabRulezLCMS Library in the week of 3rd August 2026? Check out new documents from the field of liquid phase, especially HPLC and LC/MS techniques!<blockquote>👉 <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library">SEARCH THE LARGEST REPOSITORY OF DOCUMENTS ABOUT LCMS AND RELATED TECHNIQUES</a></blockquote><blockquote>👉 Need info about different analytical techniques? Peek into <a target="_blank" rel="noopener noreferrer" href="https://gcms.labrulez.com/library">LabRulezGCMS</a> or <a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/library">LabRulezICPMS</a> libraries.</blockquote>This week we bring you posters by Agilent Technologies / ASMS, Shimadzu / ASMS, Thermo Fisher Scientific / HPLC Symposium and Waters Corporation / ASMS and application note by Metrohm!<h3>1. Agilent Technologies / ASMS: Ultra-Trace Quantification of N-Nitroso-desmethyl-sumatriptan with Interference Resolution Using LC–TQ</h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/1290_infinity_iii_uhplc_6495d_lc_tq_desmethyl_sumatriptan_asms_2026_mp_667_agilent_ebb0888227.pdf">Full PDF for download</a></li></ul>Sumatriptan succinate, an antimigraine drug contains nitrosylating functional groups and is susceptible to forming its own nitrosamine drug substance-related impurity (NDSRI), specifically N-nitroso-desmethylsumatriptan. As a Category 1 genotoxic impurity, its specification limit is established at 0.0428 ppm with respect to the API. In this study, samples and standards were prepared in methanol:water (1:1, v/v). The LC/TQ method was developed with a target limit of detection (LOD) at least 20-fold lower than the specification limit to ensure adequate sensitivity. Analytical data were collected in replicate for a 10 mg/mL API sample, as well as LOQ- and specification-level spiked samples, to evaluate recovery, relative standard deviation (RSD), linearity, and repeatability.<h4>Experimental</h4><ul><li>LC System: <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=1290+Infinity+III+UHPLC">1290 Infinity III UHPLC</a></li><li>MS: <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=6495D">6495D LC/TQ</a></li><li>Column: <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=Poroshell+120+EC+C18">Poroshell 120 EC C18</a>, 3x150mmx2.7µm, 40 Deg C</li></ul><h4>Conclusions&nbsp;</h4><ul><li>A sensitive and robust method has been developed for N-nitroso-desmethyl Sumatriptan in Sumatriptan.&nbsp;</li><li>Method LOQ is 10% lower than specification level, RSD of &lt;5%, and linearity across 0.00214 to 0.1 ppm.&nbsp;</li><li>The recovery of NDSRI in Sumatriptan at LOQ level and specification level are 95%.</li></ul><h3>2. Metrohm: Moisture analysis of rebaudioside M by Karl Fischer titration</h3>Simplified rebaudioside M moisture determination via volumetric Karl Fischer titration paired with an oven system<ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/an_k_075_download_59f185c238.pdf">Full PDF for download</a></li></ul>Natural sweeteners like stevia and its derivatives are an increasingly important part of the global sweetener market as more consumers substitute sugar with healthier alternatives. Stevia’s derivatives are significantly sweeter than table sugar. These compounds are estimated to be 50 to 300 times sweeter in comparison. This sweet taste coupled with the fact that the human body cannot metabolize steviol glycosides (i.e., they contribute zero calories to one’s diet), makes them a very attractive sugar replacement.&nbsp;The moisture content of stevia materials is a crucial factor when discussing their shelf life and stability. Measuring the moisture content of a stevia derivative, rebaudioside M, using an oven system coupled with volumetric Karl Fischer (KF) titration provided a repeatable approach for quantifying the moisture content of this material.<h4>Experimental</h4>The analysis was carried out with a Double Pt ring electrode for volumetry (6.00346.100). Testing was executed on the <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=220&amp;search=874+Oven+Sample+Processor">874 Oven Sample Processor</a> (2.874.0120) coupled with an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=220&amp;search=852+Titrando">852 Titrando</a> (2.852.0060). Approximately 0.2 g of sample was weighed into an 874 Oven Sample Processor 6 mL vial and placed onto the rack. The oven was set to a temperature of 100 °C, and the evaporated moisture was carried to the volumetric titration vessel by nitrogen gas flow at 70 mL/min. The moisture from the sample was titrated with Hydranal Comp 5 reagent.<h4>Conclusion</h4>Natural low-calorie sweeteners like stevia derivatives are growing in popularity as people choose healthier alternatives to sugar. Working to develop standardized, specific methodology can help support sweetener industry development, effective quality assessment, and the evaluation of rebaudioside M and other steviol glycosides’ stability.&nbsp;This Application Note provides a foundation for the analysis of stevia powder by Karl Fischer titration. An oven system paired with volumetric Karl Fischer analysis provides an accurate, repeatable method to evaluate stevia powder and its derivatives. This method’s compatibility with the 874 Oven Sample Processor allows increased sample throughput through automation, providing operators even more time to complete other important tasks in parallel.<h3>3. Shimadzu / ASMS: Quantitative analysis of 6 beta blockers on an LCMS-8045RX</h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/WP_131_Quantitative_analysis_of_6_beta_blockers_on_an_LCMS_8045_RX_f596f609f4.pdf">Full PDF for download</a></li></ul>Beta-adrenergic blocking agents, commonly known as beta blockers, competitively inhibit the binding of catecholamines such as epinephrine and norepinephrine to β-adrenergic receptors, thereby reducing heart rate and blood pressure. These drugs are widely prescribed for the treatment of hypertension, angina and heart failure1 . However, beta blockers may also be misused by athletes resulting in their inclusion on the World Anti-Doping Agency (WADA) prohibited list2 . Owing to both their therapeutic importance and potential misuse, sensitive and selective analytical methods are required for reliable detection and quantification. Liquid chromatography tandem mass spectrometry (LC-MS/MS) offers high sensitivity and specificity for such analyses.<h4>Method</h4>Nadolol, metoprolol, propranolol, atenolol &amp; carvedilol were purchased from Sigma Aldrich and Thermo Fisher Scientific. Standards were prepared in 1 mg/mL in LCMS grade methanol. <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=1&amp;search=Nexera+40">Nexera 40-series HPLC system</a> connected to a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=1&amp;search=LCMS-8045RX">LCMS-8045RX</a> was used for data acquisition. The mixture of standards was further diluted in LCMS grade methanol (Sigma Aldrich) and Sigmatrix urine diluent to create the standards for the calibration curves. A Shim-pack Velox Biphenyl column was used for the chromatographic separation. All analytes were ionized with electrospray ionization (ESI) in positive ion mode.<h4>Conclusion&nbsp;</h4><ul><li>Superior sensitivity in complex matrices: Limit of Detection (at accuracy ±20% and S/N &gt; 3) of 0.010 ng/mL for all the analytes evaluated in this study.</li><li>Excellent linearity and accuracy: Linear responses (with R2 &gt; 0.99) observed across the evaluated concentration range, and consistent accuracy within ±20% for all 17 calibrants included in this study.&nbsp;</li><li>Optimized throughput: Automated interface and MRM optimization via LabSolutions Connect MRM ensured maximum signal-to-noise determination for this study, while the high-organic flush at the end of each run, maintained column integrity</li></ul><h3>4. Thermo Fisher Scientific / HPLC Symposium: A switchable 2D-LC platform in PAT: routine UV monitoring or MS-based characterization of mAb PQAs directly from the bioreactor</h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/po_004764_hplc_vanquish_2dlc_mabs_analysis_bioreactor_samples_po004764_na_en_7a99c1b683.pdf">Full PDF for download</a></li></ul>Monitoring quality attributes throughout the upstream processing of mAbs is critical due to potential effects of biological variability on product safety and efficacy. Thus, there is a growing need for streamlined analytical workflows that provide timely and reliable insights to enable fast and informed process decisions.<h4>Materials and methods</h4><ul><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/743">Thermo Scientific Vanquish Flex Simple</a> Switch 2D-LC system for loop heart-cutting consisting of Quaternary Pump F (VF-P20-A), Binary Pump F (VF-P10-A-01), Dual Split Sampler FT (VF-A40-A-02), 2x Column Compartment H (VH-C10-A-03), and Diode Array Detector FG (VF-D11-A-01)&nbsp;</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1490">Thermo Scientific Orbitrap Exploris MX Mass Detector</a> (BRE725536) with BioPharma option (BRE725539)&nbsp;</li><li>Thermo Scientific MAbPac Protein A column, 12 µm, 4 x 35 mm (PN 082539)&nbsp;</li><li>Thermo Scientific ProPac 3R SCX, 2 x 50 mm, 3 µm (PN 43103-052068)&nbsp;</li><li>Thermo Scientific MAbPac SEC-1, 5 µm, 4 x 300 mm (PN 074696)</li></ul><h4>Data analysis&nbsp;</h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/76">Thermo Scientific Chromeleon 7.3.2 Chromatography Data System (CDS) </a>and <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1837">Thermo Scientific BioPharma Finder 5.2 software</a><h4>Conclusions&nbsp;</h4><ul><li>Switchable 2D-LC-UV/MS offers a streamlined approach for at-line monitoring of mAb titer, charge and size variants directly from the bioreactor in &lt;1h.&nbsp;</li><li>UV monitoring provides quick and simple trendlines, while HRAM-MS allows deep characterization at intact level.&nbsp;</li><li>Near real-time information supports in-time process decisions to protect yield and product quality.</li></ul><h3>5. Waters Corporation / ASMS: SOFTWARE TOOLS FOR AUTOMATED LC/MS ANALYSIS OF CRITICAL QUALITY ATTRIBUTES OF mRNA MOLECULES</h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/720009414_52de0bb71a.pdf">Full PDF for download</a></li></ul><div><div><section><div><div><div><div><div><div>This poster presents an automated LC-MS workflow for evaluating three critical quality attributes (CQAs) of mRNA therapeutics: 5′-capping efficiency, Poly(A) tail length and heterogeneity, and mRNA sequence integrity. A custom firefly luciferase (Fluc) mRNA construct containing a Cap-1 structure, 1,919 nucleotides, and a Poly(A) tail was used as the model sample. Importantly, all three CQAs were assessed using a single LC-MS assay, supported by specialized waters_connect software tools designed to streamline nucleic acid characterization from sequence entry through final data processing.The analytical platform consisted of a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/191">Waters ACQUITY Premier Binary UPLC System</a> with TUV detector coupled to a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1148">Xevo MRT Q-Tof Mass Spectrometer</a>, which uses multi-reflectron time-of-flight technology. Separations were performed on an ACQUITY Premier OST 1.7 µm, 300 Å, 2.1 × 150 mm column, while data-independent acquisition was carried out in MSE mode. Data processing used the <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1544">waters_connect</a> Informatics Platform together with SYNTHETIC Library 2.0, MAP Sequence 2.0, and INTACT Mass 1.9 applications. For sequence mapping, the mRNA was independently digested using four endonucleases—RNase T1, RapiZyme MC1, RapiZyme Cusativin, and human RNase4—providing complementary cleavage patterns.The workflow produced detailed information on both capping and Poly(A) tail characteristics. The Fluc mRNA showed 100% capping efficiency, with 62.7% carrying an m7GpppAm Cap-1 structure and 37.3% an m7GpppGm Cap-1 structure; no uncapped digestion product or Cap-related impurities were detected. Poly(A) tail analysis identified ten major species ranging from 98-mer to 107-mer, resulting in an average Poly(A) tail length of 102.3 nucleotides. The Xevo MRT Q-Tof provided high-resolution measurements—approximately 100,000 resolution in the examples shown—and very good mass accuracy for the detected Poly(A) species.For sequence integrity, combining the four complementary enzymatic digestions achieved 93.7% unambiguous mRNA sequence coverage, demonstrating the value of a multi-enzyme approach for comprehensive sequence confirmation. MAP Sequence 2.0 also automatically distinguished structural isomers using elevated-energy fragment-ion information, helping resolve isobaric and isomeric digestion products with less manual interpretation. Overall, the poster demonstrates that high-resolution MSE acquisition on the Xevo MRT Q-Tof combined with automated waters_connect informatics can provide an integrated and efficient approach for comprehensive characterization of key mRNA quality attributes.</div></div></div></div></div></div></section></div></div>

News from LabRulezLCMS Library - Week 32, 2026

Article

Product

Application

Academy

Video

Poster

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

SPADIA LAB is a network of state-of-the-art diagnostic laboratories and one of the largest providers of laboratory medicine in the Czech Republic. We carry out a wide range of routine, highly specialised and unique tests. We are the right choice for all doctors who wish to provide high-quality care, not only in primary healthcare but also in teaching hospitals.

SPADIA LAB

Based in Berlin, KNAUER is a medium-sized, owner-managed company that has been serving the sciences since 1962. We develop and manufacture scientific instruments of superior quality for liquid chromatography, including: Analytical HPLC/UHPLC, Preparative HPLC, Fast protein liquid chromatography (FPLC), Multi-column chromatography/Simulated moving bed (SMB) chromatography. High pressure dosing, in-line detection systems, and osmometry are additional business areas.

KNAUER

GW-0742 analysis

Targeted HPLC analysis of GW-0742 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The GW-0742 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of GW-0742 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About GW-0742</h4>GW-0742 is a synthetic research compound that acts as a selective agonist of the peroxisome proliferator-activated receptor beta/delta (PPAR-β/δ). Activation of this nuclear receptor influences the expression of genes involved in lipid and glucose metabolism, energy regulation, inflammation, and other cellular processes.Unlike selective androgen receptor modulators (SARMs), GW-0742 does not primarily act through the androgen receptor. It has been investigated mainly in preclinical studies examining metabolic, cardiovascular, and anti-inflammatory effects.<h4>Key Features</h4><ul><li>Targeted identification and quantification of GW-0742</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: GW-0742</li><li>CAS number: 317318-84-6</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for GW-0742. It does not automatically screen the sample for other PPAR agonists, SARMs, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of GW-0742 required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li>GC–MS Contamination Screening</li><li>Heavy Metals Analysis (As, Cd, Pb, Hg)</li><li>Additional Laboratory Report</li></ul>

GW-501516 analysis

Targeted HPLC analysis of GW-501516 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The GW-501516 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of GW-501516 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About GW-501516</h4>GW-501516, also known as cardarine, is a synthetic research compound that acts as a selective agonist of the peroxisome proliferator-activated receptor beta/delta (PPAR-β/δ). Activation of this nuclear receptor regulates genes involved in fatty-acid metabolism, energy utilisation, and lipid homeostasis. Unlike SARMs, GW-501516 does not act primarily through the androgen receptor.GW-501516 was investigated as a potential treatment for metabolic and cardiovascular disorders, including dyslipidaemia. It has not been approved for therapeutic use, and the World Anti-Doping Agency has issued a warning regarding its unauthorised sale and use among athletes.<h4>Key Features</h4><ul><li>Targeted identification and quantification of GW-501516</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: GW-501516</li><li>Other name: Cardarine</li><li>CAS number: 317318-70-0</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for GW-501516. It does not automatically screen the sample for other PPAR agonists, SARMs, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of GW-501516 required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li>Heavy Metals Analysis (As, Cd, Pb, Hg)</li><li>Additional Laboratory Report</li></ul>

LGD-3033 analysis

Targeted HPLC analysis of LGD-3033 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The LGD-3033 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of the target compound in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About LGD-3033</h4>LGD-3033 is an orally active, non-steroidal selective androgen receptor modulator (SARM) investigated primarily in preclinical studies. It binds to the androgen receptor and has demonstrated tissue-selective anabolic activity in animal models, particularly in muscle and bone.Preclinical research found potent activity in skeletal muscle, while its effects on androgen-sensitive tissues such as the prostate were comparatively lower at selected doses. The compound has also been investigated for its potential effects on bone density and strength.<h4>Key Features</h4><ul><li>Targeted identification and quantification of LGD-3033</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: LGD-3033</li><li>CAS number: 917891-35-1</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for the stated target compound. It does not automatically screen the sample for other SARMs, related substances, contaminants, or undeclared compounds.</li><li>For oral products, the minimum amount required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li>GC–MS Contamination Screening</li><li>Sterility Testing (TAMC/TYMC)</li><li>Heavy Metals Analysis (As, Cd, Pb, Hg)</li><li>Additional Laboratory Report</li></ul>

MK-677 analysis

Targeted HPLC analysis of MK-677 (ibutamoren) in pills, tablets, capsules, and raw API powders. The test confirms identity and determines content.

The MK-677 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of ibutamoren in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About MK-677&nbsp;</h4>MK-677, also known as ibutamoren, is an orally active, non-peptide growth hormone secretagogue. It acts as an agonist of the ghrelin receptor and stimulates the release of growth hormone, which can subsequently increase circulating levels of insulin-like growth factor 1 (IGF-1).MK-677 has been investigated in clinical and preclinical studies focusing on growth hormone secretion, body composition, muscle mass, bone metabolism, and conditions associated with growth hormone deficiency. It is not a selective androgen receptor modulator (SARM) and does not act primarily through the androgen receptor. MK-677 has not been approved by the FDA for therapeutic use.<h4>Key Features</h4><ul><li>Targeted identification and quantification of MK-677</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: MK-677</li><li>Other name: Ibutamoren</li><li>CAS number: 159634-47-6</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for MK-677. It does not automatically screen the sample for other growth hormone secretagogues, SARMs, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of MK-677 required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li>Heavy Metals Analysis (As, Cd, Pb, Hg)</li><li>Additional Laboratory Report</li></ul>

RAD-150 analysis

Targeted HPLC analysis of RAD-150 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The RAD-150 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of RAD-150 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About RAD-150</h4>RAD-150 is a synthetic research compound commonly described as a non-steroidal selective androgen receptor modulator (SARM). It is associated with androgen receptor signalling and is marketed as a structurally modified compound related to RAD-140.Unlike RAD-140, RAD-150 has not been adequately characterised in peer-reviewed preclinical or clinical studies. Information about its biological activity, pharmacokinetics, safety, and potential effects therefore remains limited.<h4>Key Features</h4><ul><li>Targeted identification and quantification of RAD-150</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: RAD-150</li><li>CAS number: 1208070-53-4</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for RAD-150. It does not automatically screen the sample for RAD-140, other SARMs, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of RAD-150 required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li>GC–MS Contamination Screening</li><li>Heavy Metals Analysis (As, Cd, Pb, Hg)</li><li>Additional Laboratory Report</li></ul>

SR-9011 analysis

Targeted HPLC analysis of SR-9011 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The SR-9011 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of SR-9011 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About SR-9011</h4>SR-9011 is a synthetic research compound commonly described as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are involved in the regulation of circadian rhythms, metabolism, sleep, and other physiological processes.SR-9011 has been investigated mainly in preclinical and laboratory studies examining circadian regulation, cellular metabolism, inflammatory processes, and cancer-cell viability. It has not been approved for therapeutic use.<h4>Key Features</h4><ul><li>Targeted identification and quantification of SR-9011</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: SR-9011</li><li>CAS number: 1379686-29-9</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for SR-9011. It does not automatically screen the sample for SR-9009, other REV-ERB agonists, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of SR-9011 required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li>GC–MS Contamination Screening</li><li>Heavy Metals Analysis (As, Cd, Pb, Hg)</li><li>Additional Laboratory Report</li></ul>

Bronchogen Analysis

HPLC analysis of Bronchogen for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of Bronchogen in lyophilized samples and raw API powders. HPLC testing provides information about the target peptide content of the sample and its proportion relative to chromatographically detectable impurities.<h4>Bronchogen</h4>Bronchogen is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Leu. Scientific studies have investigated it primarily in experimental models involving bronchial epithelium and lung tissue.The molecule consists of only four amino acid residues. HPLC analysis confirms the presence of Bronchogen in the sample, determines its amount and evaluates peptide purity.<h4>What the Analysis Determines</h4><ul><li>Identity of Bronchogen</li><li>Amount of Bronchogen in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Bronchogen</li><li>Sequence: Ala-Glu-Asp-Leu</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of Bronchogen in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5>Endotoxin Analysis</h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5>CHNS Mass Report</h5>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).<h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5>LC-MS Screening for Peptide Contamination</h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5>Sterility Testing</h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5>Heavy Metals Analysis</h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Cagrilintide analysis

HPLC analysis of cagrilintide for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of cagrilintide in lyophilized samples and raw API powders. HPLC testing provides information about the actual content of the target peptide and its purity relative to chromatographically detectable impurities.<h4>Cagrilintide</h4>Cagrilintide is a synthetic, lipidated, long-acting amylin analogue. Its molecular structure was developed to improve stability and extend its duration of action compared with native amylin. Scientific and clinical literature describes cagrilintide as an investigational peptide rather than a generally available approved active substance.Its structure contains modified amino acid residues and an amidated C-terminus. The stated molecular weight is approximately 4,409 Da.HPLC analysis confirms the presence of cagrilintide in the sample, determines its amount and evaluates peptide purity.<h4>What the Analysis Determines</h4><ul><li>Identity of cagrilintide</li><li>Amount of cagrilintide in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: cagrilintide</li><li>CAS number: 1415456-99-3</li><li>Molecular weight: 4,409 Da</li><li>Sequence: Unk-Glu-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Vas-Gly-Ser-Asn-Thr-Pro-NH2</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of cagrilintide in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5>Endotoxin Analysis</h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5>CHNS Mass Report</h5>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).<h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5>LC-MS Screening for Peptide Contamination</h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5>Sterility Testing</h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5>Heavy Metals Analysis</h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Clomiphene analysis

Targeted HPLC analysis of clomiphene in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Clomiphene Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of clomiphene in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Clomiphene&nbsp;</h4>Clomiphene, also known by the trade name Clomid, is an orally active, non-steroidal selective estrogen receptor modulator (SERM). It interacts with estrogen receptors and can exert estrogenic or anti-estrogenic effects depending on the target tissue. Clomiphene is used clinically to induce ovulation in selected patients with ovulatory dysfunction.The compound is commonly administered as clomiphene citrate and consists of two geometric isomers, enclomiphene and zuclomiphene, which differ in their biological properties.<h4>Key Features</h4><ul><li>Targeted identification and quantification of clomiphene</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Clomiphene</li><li>Other name: Clomid</li><li>CAS number: 911-45-5</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 5 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for clomiphene. It does not automatically screen the sample for enclomiphene, zuclomiphene, other selective estrogen receptor modulators, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of clomiphene required for evaluation is 5 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li>GC–MS Contamination Screening</li><li>Heavy Metals Analysis (As, Cd, Pb, Hg)</li><li>Additional Laboratory Report</li></ul>

Cagrilintide/Semaglutide (CagriSema) blend analysis

HPLC analysis of a CagriSema blend for identification and separate quantification of cagrilintide and semaglutide in mg per vial.

This analysis is designed to confirm the identity and separately determine the amount of cagrilintide and semaglutide in a combined lyophilized sample. HPLC testing measures the content of both target peptides, with results reported in mg per vial.Peptide purity cannot be reliably determined in a blend because impurities originating from the individual peptides may overlap in the chromatographic data and cannot be clearly attributed to a specific component.<h4>CagriSema</h4>CagriSema refers to a combination of cagrilintide and semaglutide in a single product. Cagrilintide is a synthetic lipidated amylin analogue, while semaglutide is a modified GLP-1 peptide analogue.Because the sample contains two different peptide components, the analysis focuses on confirming their identity and separately determining the amount of each peptide. The report therefore provides individual results for cagrilintide and semaglutide.<h4>What the Analysis Determines</h4><ul><li>Identity of cagrilintide</li><li>Identity of semaglutide</li><li>Amount of cagrilintide in the sample</li><li>Amount of semaglutide in the sample</li><li>Results in mg per vial for each target peptide</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: cagrilintide and semaglutide</li><li>Blend name: CagriSema</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format: mg per vial for each target peptide</li><li>Minimum sample amount: one whole unopened vial containing the lyophilizate</li><li>Average turnaround time: 7 business days</li><li>Peptide purity: not measured</li></ul><blockquote><h5>Important Notice</h5>Peptide purity cannot be determined for a cagrilintide/semaglutide blend. Impurities associated with both peptides may overlap in the chromatographic data and cannot be reliably assigned to the individual target compounds.The final report provides identification and separately measured amounts of cagrilintide and semaglutide. Peptide purity is not included in the results.</blockquote><h4>Additional Analyses</h4><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5>Endotoxin Analysis</h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5>LC-MS Screening for Peptide Contamination</h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5>Sterility Testing</h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5>Heavy Metals Analysis</h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Products focused on HPLC - page 2

Related content

News from LabRulezLCMS Library - Week 32, 2026

Efficient Sample Evaporation Using the Organomation MULTIVAP® Nitrogen Evaporator

Pipetting Made Easy - Part 3: Pipette Selection